OA10355A - 1,5 Benzodiazepine derivatives having cck antagonistic or agonistic activity - Google Patents

1,5 Benzodiazepine derivatives having cck antagonistic or agonistic activity Download PDF

Info

Publication number
OA10355A
OA10355A OA60722A OA60722A OA10355A OA 10355 A OA10355 A OA 10355A OA 60722 A OA60722 A OA 60722A OA 60722 A OA60722 A OA 60722A OA 10355 A OA10355 A OA 10355A
Authority
OA
OAPI
Prior art keywords
phenyl
formula
group
4alkyl
compound
Prior art date
Application number
OA60722A
Other languages
English (en)
Inventor
Elizabeth Ellen Sugg
Christopher Joseph Aquino
Jerzy Ryszard Szewczyk
Harry Finch
Robin Arthur Ellis Carr
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of OA10355A publication Critical patent/OA10355A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0827Tripeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
OA60722A 1993-04-15 1995-10-12 1,5 Benzodiazepine derivatives having cck antagonistic or agonistic activity OA10355A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939307833A GB9307833D0 (en) 1993-04-15 1993-04-15 Modulators of cholecystokinin and gastrin

Publications (1)

Publication Number Publication Date
OA10355A true OA10355A (en) 2001-10-19

Family

ID=10733915

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60722A OA10355A (en) 1993-04-15 1995-10-12 1,5 Benzodiazepine derivatives having cck antagonistic or agonistic activity

Country Status (34)

Country Link
US (2) US5646140A (pt)
EP (1) EP0694039B1 (pt)
JP (1) JP3406317B2 (pt)
KR (1) KR100364948B1 (pt)
CN (1) CN1058487C (pt)
AP (2) AP512A (pt)
AT (1) ATE198894T1 (pt)
AU (1) AU681139B2 (pt)
CA (1) CA2158973C (pt)
CZ (1) CZ286695B6 (pt)
DE (1) DE69426624T2 (pt)
DK (1) DK0694039T3 (pt)
EC (1) ECSP941066A (pt)
ES (1) ES2154674T3 (pt)
FI (1) FI954853A0 (pt)
GB (1) GB9307833D0 (pt)
GR (1) GR3035641T3 (pt)
HK (1) HK1003943A1 (pt)
HU (1) HU223467B1 (pt)
IL (2) IL109316A (pt)
IS (2) IS4147A (pt)
MY (2) MY131569A (pt)
NO (1) NO311133B1 (pt)
NZ (1) NZ265272A (pt)
OA (1) OA10355A (pt)
PE (2) PE50994A1 (pt)
PH (1) PH30897A (pt)
PL (1) PL178790B1 (pt)
PT (1) PT694039E (pt)
RU (1) RU2135486C1 (pt)
SK (1) SK281211B6 (pt)
TW (1) TW487703B (pt)
WO (1) WO1994024149A1 (pt)
ZA (2) ZA942570B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3621416B2 (ja) * 1993-12-28 2005-02-16 塩野義製薬株式会社 新規なベンゾジアゼピン誘導体
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
PL180026B1 (pl) * 1994-04-14 2000-12-29 Glaxo Wellcome Inc Pochodne 5-heterocyklo-1,5-benzodiazepiny, sposób ich wytwarzania oraz kompozycja zawierajaca te zwiazki PL PL PL PL PL PL PL PL
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
US5795887A (en) * 1994-04-15 1998-08-18 Glaxo Wellcome Inc. Method of inducing cholecystokinin agonist activity using 1,4- Benzodiazepine compounds
US5780464A (en) * 1994-10-14 1998-07-14 Glaxo Wellcome Inc. Enteric coated compositions of 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity
GB9420748D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
US5910495A (en) * 1994-10-14 1999-06-08 Glaxo Wellcome Inc. Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
GB9420747D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
AU715611B2 (en) 1995-12-11 2000-02-03 New England Medical Center Hospitals, Inc., The Assay for and uses of peptide hormone receptor ligands
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
ATE248823T1 (de) * 1996-12-10 2003-09-15 Zeria Pharm Co Ltd 1,5-benzodiazepinderivate
PL196015B1 (pl) 1997-04-15 2007-11-30 Csir Zastosowanie ekstraktu roślinnego i nieterapeutyczny sposób hamowania łaknienia
AR022044A1 (es) * 1999-05-06 2002-09-04 Glaxo Group Ltd Derivados de 1,5-benzodiazepina
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
US20020180095A1 (en) * 2001-05-29 2002-12-05 Berard Steven O. Thermally conductive carbon fiber extrusion compounder and method of using same
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ES2319886T3 (es) * 2002-02-20 2009-05-14 Abbott Laboratories Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1).
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
JP4069159B2 (ja) * 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ[e]アズレン誘導体及びそれらのアナログ
CN1333077C (zh) * 2005-04-15 2007-08-22 华南农业大学 缩胆囊素活性片段的串联表达及其应用
ATE553093T1 (de) * 2006-08-25 2012-04-15 Abbott Lab Indazolderivate zur hemmung von trpv1 und verwendungen davon
JP2010513557A (ja) 2006-12-20 2010-04-30 アボット・ラボラトリーズ 疼痛治療のためのtrpv1バニロイド受容体アンタゴニストとしてのn−(5,6,7,8−テトラヒドロナフタレン−1−イル)尿素誘導体および関連化合物
EP2489660A1 (en) * 2008-03-20 2012-08-22 Abbott Laboratories Methods for making central nervous system agents that are TRPV1 antagonists
CN103102285B (zh) * 2013-01-30 2015-07-29 淮阴师范学院 对氨基苯乙腈的制备方法
CN110627770A (zh) 2013-11-18 2019-12-31 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
PL3324977T3 (pl) 2015-07-22 2022-11-14 Enanta Pharmaceuticals, Inc. Pochodne benzodiazepiny jako inhibitory rsv
KR20180114910A (ko) 2016-02-05 2018-10-19 데날리 테라퓨틱스 인크. 수용체-상호작용 단백질 키나제 1의 억제제
DK3552017T3 (da) 2016-12-09 2022-05-16 Denali Therapeutics Inc Forbindelser, der er anvendelige som ripk1-inhibitorer
AU2018221820B2 (en) 2017-02-16 2023-11-02 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
US10752598B2 (en) * 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
CN111386118B (zh) 2017-09-29 2023-05-09 英安塔制药有限公司 作为rsv抑制剂的组合药物剂
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11254664B2 (en) 2019-03-18 2022-02-22 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US11999750B2 (en) 2022-01-12 2024-06-04 Denali Therapeutics Inc. Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641280B1 (fr) * 1988-12-29 1994-01-21 Roussel Uclaf Nouveaux derives de la 2,4-dioxo 2,3,4,5-tetrahydro 1h-1,5-benzodiazepine, leur procede de preparation et leur application comme medicaments
FR2659653B1 (fr) * 1990-03-13 1992-05-22 Rhone Poulenc Sante Derives de l'uree, leur preparation et les medicaments les contenant.
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JP2904941B2 (ja) * 1991-01-28 1999-06-14 出光興産株式会社 スチレン系重合体の精製方法
GB9201180D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
PL180026B1 (pl) * 1994-04-14 2000-12-29 Glaxo Wellcome Inc Pochodne 5-heterocyklo-1,5-benzodiazepiny, sposób ich wytwarzania oraz kompozycja zawierajaca te zwiazki PL PL PL PL PL PL PL PL

Also Published As

Publication number Publication date
NO311133B1 (no) 2001-10-15
WO1994024149A1 (en) 1994-10-27
US5585376A (en) 1996-12-17
SK281211B6 (sk) 2001-01-18
PT694039E (pt) 2001-06-29
CA2158973A1 (en) 1994-10-27
GR3035641T3 (en) 2001-06-29
PL311084A1 (en) 1996-02-05
AU681139B2 (en) 1997-08-21
HK1003943A1 (en) 1998-11-13
ZA942571B (en) 1994-11-11
IL109315A0 (en) 1994-07-31
TW487703B (en) 2002-05-21
EP0694039A1 (en) 1996-01-31
JP3406317B2 (ja) 2003-05-12
PH30897A (en) 1997-12-23
FI954853A (fi) 1995-10-12
DE69426624D1 (de) 2001-03-01
PE50594A1 (es) 1995-01-06
AP9400635A0 (en) 1994-04-30
GB9307833D0 (en) 1993-06-02
PL178790B1 (pl) 2000-06-30
IL109316A0 (en) 1994-07-31
AP512A (en) 1996-07-29
KR100364948B1 (ko) 2003-03-29
SK125395A3 (en) 1996-06-05
CZ267595A3 (en) 1996-04-17
AP462A (en) 1996-02-19
HUT74102A (en) 1996-11-28
US5646140A (en) 1997-07-08
HU223467B1 (hu) 2004-07-28
MY112237A (en) 2001-05-31
CN1120843A (zh) 1996-04-17
RU2135486C1 (ru) 1999-08-27
ZA942570B (en) 1994-11-11
IS4147A (is) 1994-10-16
AP9400634A0 (en) 1994-04-30
NZ265272A (en) 1997-07-27
AU6567694A (en) 1994-11-08
FI954853A0 (fi) 1995-10-12
ATE198894T1 (de) 2001-02-15
MY131569A (en) 2007-08-30
ECSP941066A (es) 1994-11-16
NO954090L (no) 1995-12-13
CA2158973C (en) 2006-06-06
HU9502978D0 (en) 1995-12-28
IS4148A (is) 1994-10-16
PE50994A1 (es) 1995-01-06
CZ286695B6 (en) 2000-06-14
DE69426624T2 (de) 2001-06-21
ES2154674T3 (es) 2001-04-16
DK0694039T3 (da) 2001-05-21
IL109316A (en) 1999-03-12
CN1058487C (zh) 2000-11-15
EP0694039B1 (en) 2001-01-24
NO954090D0 (no) 1995-10-13
JPH08508744A (ja) 1996-09-17

Similar Documents

Publication Publication Date Title
OA10355A (en) 1,5 Benzodiazepine derivatives having cck antagonistic or agonistic activity
AU679085B2 (en) Benzodiazepine analogs
US5795887A (en) Method of inducing cholecystokinin agonist activity using 1,4- Benzodiazepine compounds
US5739129A (en) CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
EP0756602B1 (en) Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
US5686449A (en) 1,5-benzodiazepines useful as gastrinor CCK-antagonists
US5910495A (en) Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
OA10236A (en) 1,5 Benzodiazepine derivatives having cck and/or gastrin antagonistic activity
US5739162A (en) Carbamoylmethylurea derivatives